Increased prevalence, incidence, and female predominance of multiple sclerosis in northern Japan
Introduction
In most patients with multiple sclerosis (MS), disease onset is in the third or fourth decade of life with its peak in the most economically productive years [1]. The most striking epidemiological characteristic is the apparent uneven distribution of the disease across the world, and the interplay between genes and the geographically determined physical environment are important factors for the different prevalence of MS [2]. Several studies have suggested an increasing prevalence of MS worldwide [3], [4], [5]. Although incidence studies are rarer than prevalence studies, some have shown that the annual MS incidence rates have gradually increased over the last 30 years [3], [6], [7], [8].
MS prevalence had been considered low (0.8–4.0/100,000 persons) in Japan [9]. In 2001, we conducted a survey of the prevalence of MS in Tokachi province and showed that it was not as low as expected in northern Japan (8.6/100,000 persons) [10]. We conducted a second survey in the same province in 2006 and reported that the prevalence of MS was increasing (13.1/100,000 persons) [11]. The proportion of optic-spinal MS (OSMS) is considered to be high in Asia, although we [10] and others [12] reported that this is not the case in northern Japan (3–16%). In 2006, Wingerchuk et al. proposed criteria for the diagnosis of neuromyelitis optica (NMO) [13], and most patients with OSMS have been considered to have NMO. To date, there are no data regarding the prevalence of NMO in Japan.
In this third epidemiologic surveillance of MS in Tokachi province, we investigated whether MS prevalence has increased over the last 10 years. In the present study, we excluded cases of NMO using the criteria of Poser et al. [14], and we surveyed the prevalence of NMO in northern Japan for the first time. In Europe, the female/male MS ratio has been increasing over the last decade [1]. We investigated whether the same tendency can also be seen in northern Japan. However, the incidence rate is a better measure of the risk of MS, because it is independent of survival time, and prevalence can be indicative of several other factors such as diagnostic accuracy and ascertainment probability besides the true frequency of MS [2]. Taken together, we were also able to assess the incidence of MS over the last 30 years.
Section snippets
Study area and study population
This third survey was conducted in Tokachi province located on Hokkaido, the northernmost island of Japan, in March 2011, using the same methods as in the previous studies in 2001 and 2006 [10], [11]. The official population of Tokachi province according to the Government Census Office was 352,353 (169,249 men and 183,104 women) at the end of March 2011. The population in the community decreased by 9,373 from 2001 to 2011 (361,726 in 2001); however, the population has stabilized between 350,000
Prevalence
On the prevalence day (March 31, 2011), 60 patients (47 female and 13 male) residing in the study area, were included in the study as they exhibited clinically definite or laboratory-supported definite MS according to the criteria of Poser et al. [14]. Of these 60 patients, 50 were diagnosed by one of the authors (H.H.). In the previous two studies [10], [11], the crude prevalence of MS was calculated at this stage 8.6/100,000 persons in 2001 and 13.1/100,000 persons in 2006. In the present
Discussion
There have been many reported MS prevalence studies, but it is sometimes difficult to accurately determine the change of prevalence because of migration and population changes. As population size may be an important source of bias, MS studies should investigate populations of comparable size [23]. As a general principle, the use of very large populations provides more precise estimates but is subject to several problems: loss of detail, ethnic heterogeneity, and high cost, as well as difficulty
Conflict of interest
Dr. Houzen has no conflicts of interest to disclose. Dr. Niino receives research support from Grants-in-Aid for Scientific Research from the Ministry of Health, Labor and Welfare of Japan and the National Hospital Organization of Japan, serves on a scientific advisory board for Biogen Idec, and has received speaker honoraria from Biogen Idec, Bayer Schering Pharma, Asahi Kasei Kuraray Medical Co., Ltd, and Novartis Pharma. Dr. Hirotani has no conflicts of interest to disclose. Dr. Fukazawa
Acknowledgments
We thank the following colleagues for enrolling patients in the study: Dr. Kondo, Department of Neurology, Hokuto Hospital; Dr. Kamaya, Department of Neurology, Obihiro Nishi Hospital; and Dr. Maeda, Department of Medicine, Kurosawa Hospital.
References (32)
- et al.
The changing demographic pattern of multiple sclerosis epidemiology
Lancet Neurol
(2010) - et al.
The prevalence and clinical characteristics of MS in northern Japan
J Neurol Sci
(2003) - et al.
Prevalence of multiple sclerosis in Asahikawa, a city in northern Japan
J Neurol Sci
(2003) - et al.
Heterogeneity and continuum of multiple sclerosis phenotypes in Japanese according to the results of the fourth nationwide survey
J Neurol Sci
(2009) Multiple sclerosis in the Japanese population
Lancet Neurol
(2003)- et al.
The increasing incidence and prevalence of female multiple sclerosis—a critical analysis of potential environmental factors
Autoimmun Rev
(2011) - et al.
Sex ratio of multiple sclerosis in Canada: a longitudinal study
Lancet Neurol
(2006) - et al.
Epidemiology of multiple sclerosis in Europe: a review
Int Rev Psychiatry
(2010) - et al.
A 50-year follow-up of the incidence of multiple sclerosis in Hordaland County, Norway
Neurology
(2006) - et al.
Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan
Neurology
(2007)
The rising prevalence and changing age distribution of multiple sclerosis in Manitoba
Neurology
Increasing incidence of multiple sclerosis in the province of Sassari, northern Sardinia
Neuroepidemiology
Possible increasing risk of multiple sclerosis in Catania, Sicily
Neurology
Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000
Neurology
Prevalence of multiple sclerosis and its north-to-south gradient in Japan
Neuroepidemiology
Increasing prevalence and incidence of multiple sclerosis in northern Japan
Mult Scler
Cited by (83)
Multiple sclerosis prevalence and its relationship with economic status in Afyonkarahisar, Turkey: Afyonkarahisar, Turkey: Multiple Sclerosis and Economic Status
2024, Multiple Sclerosis and Related DisordersDynamic changes in patient admission and their disabilities in multiple sclerosis and neuromyelitis optica: A Japanese nationwide administrative data study
2024, Multiple Sclerosis and Related DisordersThe prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan
2023, Multiple Sclerosis and Related DisordersMultiple sclerosis incidence temporal trend in the Northeast of Iran: Using the Empirical Bayesian method
2023, Multiple Sclerosis and Related DisordersCitation Excerpt :However, a study conducted in Markazi Province has shown that the incidence of MS has decreased from 15.43 in 2010 to 7.51 in 2019 (Faraji et al., 2022). Also, similar to our findings, an increase in MS incidence has been reported in different global regions such as Finland (Sumelahti et al., 2014), France (Debouverie et al., 2007), Italy (Grassivaro et al., 2019), Greece (Papathanasopoulos et al., 2008), Australia (Ribbons et al., 2017), Japan (Houzen et al., 2012), and Kuwait (Alroughani et al., 2014). In addition to genetic predisposition, some studies have shown that Iranians are genetically close to Europeans, who are an ethnic group prone to MS (Smestad et al., 2008; Cavalli-Sforza et al., 1988), many risk factors can be related to the high incidence and increasing trend of MS, which have been discussed follows.
Vitamin D and the epidemiology of multiple sclerosis
2023, Feldman and Pike's Vitamin D: Volume Two: Disease and Therapeutics